These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 30502651)
1. Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells. Kell SA; Kachura MA; Renn A; Traquina P; Coffman RL; Campbell JD Int Immunopharmacol; 2019 Jan; 66():296-308. PubMed ID: 30502651 [TBL] [Abstract][Full Text] [Related]
2. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients. Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766 [TBL] [Abstract][Full Text] [Related]
3. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer]. Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109 [TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor agonists induce apoptosis in mouse B-cell lymphoma cells by altering NF-κB activation. Arunkumar N; Liu C; Hang H; Song W Cell Mol Immunol; 2013 Jul; 10(4):360-72. PubMed ID: 23727784 [TBL] [Abstract][Full Text] [Related]
5. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053 [TBL] [Abstract][Full Text] [Related]
6. Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Abel K; Wang Y; Fritts L; Sanchez E; Chung E; Fitzgerald-Bocarsly P; Krieg AM; Miller CJ Clin Diagn Lab Immunol; 2005 May; 12(5):606-21. PubMed ID: 15879022 [TBL] [Abstract][Full Text] [Related]
7. [Toll-like receptor 9 in cpG oligodeoxynucleotides-induced species-specific immune responses]. Li N; Fan XG; Tang SE; Zhu C Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Oct; 30(5):533-5. PubMed ID: 16320582 [TBL] [Abstract][Full Text] [Related]
8. Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade. Li T; Hua C; Yue W; Wu J; Lv X; Wei Q; Zhu S; Zang G; Cui J; Liu YJ; Chen J Pharmacol Res; 2020 Nov; 161():105293. PubMed ID: 33176206 [TBL] [Abstract][Full Text] [Related]
9. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses. Merlo A; Calcaterra C; Mènard S; Balsari A J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660 [TBL] [Abstract][Full Text] [Related]
10. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Vollmer J; Weeratna RD; Jurk M; Samulowitz U; McCluskie MJ; Payette P; Davis HL; Schetter C; Krieg AM Immunology; 2004 Oct; 113(2):212-23. PubMed ID: 15379982 [TBL] [Abstract][Full Text] [Related]
11. A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer. Garon EB; Spira AI; Johnson M; Bazhenova L; Leach J; Cummings AL; Candia A; Coffman RL; Janatpour MJ; Janssen R; Gamelin E; Chow LQM Clin Cancer Res; 2021 Aug; 27(16):4566-4573. PubMed ID: 34108179 [TBL] [Abstract][Full Text] [Related]
13. The immunostimulatory effect of CpG oligodeoxynucleotides on peripheral blood mononuclear cells of healthy dogs and dogs with atopic dermatitis. Jassies-van der Lee A; Rutten V; Spiering R; van Kooten P; Willemse T; Broere F Vet J; 2014 Apr; 200(1):103-8. PubMed ID: 24461202 [TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases. Sfondrini L; Sommariva M; Tortoreto M; Meini A; Piconese S; Calvaruso M; Van Rooijen N; Bonecchi R; Zaffaroni N; Colombo MP; Tagliabue E; Balsari A Int J Cancer; 2013 Jul; 133(2):383-93. PubMed ID: 23319306 [TBL] [Abstract][Full Text] [Related]
15. Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells. Booth JS; Nichani AK; Benjamin P; Dar A; Krieg AM; Babiuk LA; Mutwiri GK Vet Immunol Immunopathol; 2007 Jan; 115(1-2):24-34. PubMed ID: 17067685 [TBL] [Abstract][Full Text] [Related]
16. Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4 Gallotta M; Assi H; Degagné É; Kannan SK; Coffman RL; Guiducci C Cancer Res; 2018 Sep; 78(17):4943-4956. PubMed ID: 29945961 [TBL] [Abstract][Full Text] [Related]
17. CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans. Campbell JD; Cho Y; Foster ML; Kanzler H; Kachura MA; Lum JA; Ratcliffe MJ; Sathe A; Leishman AJ; Bahl A; McHale M; Coffman RL; Hessel EM J Clin Invest; 2009 Sep; 119(9):2564-76. PubMed ID: 19726873 [TBL] [Abstract][Full Text] [Related]
18. Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif. Zhang Y; Shoda LK; Brayton KA; Estes DM; Palmer GH; Brown WC J Interferon Cytokine Res; 2001 Oct; 21(10):871-81. PubMed ID: 11711000 [TBL] [Abstract][Full Text] [Related]
19. Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction. Yu D; Putta MR; Bhagat L; Dai M; Wang D; Trombino AF; Sullivan T; Kandimalla ER; Agrawal S Antimicrob Agents Chemother; 2008 Dec; 52(12):4320-5. PubMed ID: 18852281 [TBL] [Abstract][Full Text] [Related]
20. The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. Pradhan P; Qin H; Leleux JA; Gwak D; Sakamaki I; Kwak LW; Roy K Biomaterials; 2014 Jul; 35(21):5491-504. PubMed ID: 24720881 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]